SBI Healthcare Opportunities Fund delivered a 15.8% one-year return, significantly outperforming its benchmark of 4.4%. While it leads the one-year rankings, peers like ICICI Prudential Pharma Healthcare & Diagnostics Fund show stronger three-year results. Sectoral funds carry high concentration risk, so investors should look at long-term consistency rather than short-term returns.
What Happened
The SBI Healthcare Opportunities Fund has outperformed its benchmark index by a wide margin in the last one-year period. The fund reported a compound annual growth rate (CAGR) of 15.8%, while the benchmark index recorded a return of 4.4%. This 11.4 percentage point difference highlights the fund's recent success in navigating the pharmaceutical and healthcare sector, which is a specialized area of the stock market.
Peer Performance Check
When evaluating mutual funds, a single fund's performance is only part of the picture. The broader category includes several other funds with different track records. For example, the Mirae Asset Healthcare Fund and DSP Healthcare Fund posted one-year CAGR returns of 15.4% and 11.4%, respectively.
Among funds with over Rs 1,500 crore in assets under management (AUM), the Nippon India Pharma Fund holds the largest corpus at Rs 8,635.7 crore, though its one-year return stood at 8.8%. When shifting the focus to a three-year timeframe, the ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund emerges as a top performer in this group, delivering a return of 26.4%. This variation shows that funds often alternate in leadership depending on the time period measured.
Why Timeframes Matter
Investors often make the mistake of looking only at the most recent returns. However, the SBI Healthcare Opportunities Fund also showed strength over longer periods, with a 24.4% CAGR over three years. Similarly, it demonstrated resilience in shorter windows, with returns of 18.5% over three months and 13.9% over six months. Comparing funds across both one-year and three-year periods helps investors understand whether a fund's success is due to consistent strategy or a short-term market fluctuation.
The Risk Of Sectoral Funds
Sectoral funds, like those focused on pharma and healthcare, are inherently different from diversified equity mutual funds. A diversified fund spreads investments across many sectors like banking, IT, and manufacturing, which helps balance risk. In contrast, a sectoral fund puts most of its money into one industry.
This means that if the pharma sector faces problems—such as drug price controls, export restrictions, or raw material supply issues—the entire fund's performance can drop quickly. Investors should be aware that these funds are more volatile and typically better suited as a small part of a larger portfolio, rather than a core holding.
What To Watch Next
For those evaluating these funds, the key monitorables are consistency and costs. Investors may track the fund manager's ability to maintain performance across different market cycles. Additionally, checking the expense ratio—the annual fee charged by the fund—is important, as it directly impacts net returns. Finally, market updates regarding drug pricing policies and global healthcare demand will continue to influence how these sectoral funds perform in the coming quarters.